You are here

DEVELOPMENT OF INHIBITORS AGAINST HCV INFECTION

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI049592-01A1
Agency Tracking Number: AI049592
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
ZYMETX, INC. 800 RESEARCH PKY, STE 100
OKLAHOMA CITY, OK 73104
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOSHUA OJWANG
 (405) 271-1314
 OJWANGJ@ZYMETX.COM
Business Contact
 NORMAN PROULX
Phone: (405) 271-1314
Email: PROULXN@ZYMETX.COM
Research Institution
N/A
Abstract

DESCRIPTION (Provided by applicant): Hepatitis C viral infection is the most
common chronic bloodborne infection in the United States. There are about
36,000 new infections every year, and 25-30 percent of those infections are
symptomatic. It is estimated that 3.9 million (1.8 percent) Americans have been
infected. Chronic liver disease, which is caused by HCV infection, is the tenth
leading cause of death among adults in the United States, accounting for
approximately 1 percent of all deaths. To date, there is no efficient culture
system available to evaluate the activity of compounds against HCV in vitro. To
overcome this difficulty, surrogate animal viruses are being used, including
bovine viral diarrhea virus, yellow fever virus, dengue virus, and banzi virus.
We have identified a compound (ZX-2401) that shows a significant antiviral
activity against these surrogate viruses. The overall scope of this application
is to investigate the feasibility of this compound and its derivatives as
potential inhibitors of HCV. The specific aims for these novel compounds
include synthesizing ZX-2401 or derivatives as needed for the proposed studies,
performing in vitro antiviral studies in HCV replicon system and cytotoxicity
testing, performing studies in combination with IFN-alpha, and performing
mechanism of action studies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government